Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1506573 | 1.00 | TSHR (0.50) | TSHRKDM4ESMN1; SMN2POLBALDH1A1 | |
| SCHEMBL13247979 | 0.82 | LGMN (0.49) | TSHRKDM4ESMN1; SMN2POLBALDH1A1 | |
| SCHEMBL3001843 | 0.82 | LGMN (0.49) | TSHRKDM4ESMN1; SMN2POLBALDH1A1 | |
| SCHEMBL3001844 | 0.82 | LGMN (0.49) | TSHRKDM4ESMN1; SMN2POLBALDH1A1 | |
| SCHEMBL13247944 | 0.81 | ALDH1A1 (0.44) | TSHRKDM4ESMN1; SMN2POLBALDH1A1 | |
| Hydrochloric Acid SCHEMBL2990944 | 0.81 | LGMN (0.48) | TSHRKDM4ESMN1; SMN2POLBALDH1A1 | |
| Hydrochloric Acid SCHEMBL2990942 | 0.81 | LGMN (0.48) | TSHRKDM4ESMN1; SMN2POLBALDH1A1 | |
| SCHEMBL2548786 | 0.81 | ALDH1A1 (0.51) | TSHRKDM4ESMN1; SMN2POLBALDH1A1 | |
| SCHEMBL13345937 | 0.80 | ALDH1A1 (0.45) | TSHRKDM4ESMN1; SMN2POLBALDH1A1 | |
| SCHEMBL5024448 | 0.79 | NPC1 (0.51) | ALDH1A1MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971595-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2013-10-16 | — | — | EP | disclosed |
| US-7910592-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20090042892-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042892-A1 | Cetp Inhibitors | CETP, APOB, MTTP | TSHR 3089/4885KDM4E 2213/4885SMN1; SMN2 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.